期刊文献+

一种新的静注人免疫球蛋白制剂制备工艺的研究 被引量:5

Preparation of a new human immunoglobulin for intravenous injection
下载PDF
导出
摘要 目的初步探讨一种新的静注人免疫球蛋白的制备工艺对制品得率和主要质量指标的影响。方法以组分Ⅱ+Ⅲ经过溶解、辛酸沉淀、Capto-Q层析、Macrocap-Q层析、收集流穿液,经超滤、浓缩,制备静注人免疫球蛋白,检测蛋白液中Ig A、Ig M、白蛋白、PKA、ACA含量、纯度、收率,并与低温乙醇法比较。结果与低温乙醇法比较,辛酸沉淀法可显著降低制品中Ig A、Ig M、白蛋白、PKA含量,提高产品得率。结论采用辛酸沉淀工艺制备静注人免疫球蛋白可提高制品的质量和产量。 Objective To prepare a new human immunoglobulin product for intravenous injection. Methods The human immunoglobulin for intravenous injection was prepared by melting component Ⅱ+Ⅲ, followed by octanoic acid precipitation, Capto-Q chromatography, Macrocap-Q chromatography, ultrafiltration and concentration. The Ig A, Ig M, albumin, PKA, ACA content, purity, and yeild were tested and compared with those with low temperature ethanol extraction method. Results Compared with the low temperature ethanol extraction method, octanoic acid precipitation significantly reduced the content of Ig A, Ig M, albumin and PKA, and improved the product recovery rate. Conclusion Octanoic acid precipitation can improve the quality and yield of intravenous human immunoglobulin.
出处 《中南药学》 CAS 2015年第4期376-378,共3页 Central South Pharmacy
关键词 静注人免疫球蛋白 辛酸沉淀法 低温乙醇法 human immunoglobulin for intravenous injection octanoic acid precipitation low temperature ethanol extraction method
  • 相关文献

参考文献4

二级参考文献27

  • 1任跃明,程雅琴,倪道明.静脉注射人免疫球蛋白的质量控制[J].中国生物制品学杂志,2005,18(1):73-75. 被引量:12
  • 2Buchacher A, lberer G. Purification of intravenous immunoglobulin G from human plasma - aspects of yield and virus safety [J]. Biotchnol J,2006, ( 1 ) : 148 - 163
  • 3Gelfand EW. Difference between IVIG prouducts : Imapct on clinical outcome [J]. Int Immunopharmacol, 2006, ( 6 ) : 592-599
  • 4Siegel J, Fashp PD. The product : all intravenous immunoglobulins are not equivalent [..l]. Pharmacotherapy,2005,25(11 Pt 2) :785-845
  • 5Erwin W,Gelfand MD. Clinical consideratinons in IVIG treatment selction [C]//The 2006 American Socilty of Heath-sysem Pharmacists Midyear Clinical Meeting and Exhibition. CTE34606 newsletter V6.qxp 2121/2007.2006:7-10
  • 6Gelfand EW, Goldsmith J,leelelman H. Primary humoral immunodeficiency :optimizing IgG replacement therapy [J]. Immun Defic Founda :Clin Focus, 2003(10): 3-15
  • 7Buchacher A,Ibeer G.Purification of introvenous immunoglobulin G form human plasma-aspeets of yield and virus safaty [J]. Biotchnol J,2006,2(1):42-57
  • 8WHO Expert Committee on Biolgical standardiczation.Guidenlines on viral inactivation and removal procdeures intended to assure the viral safety of human blood plasma products[S]. Geneva : WHO, 2001 - 11-26-30
  • 9Wolberg AS, Kon R.H, Monroe DM, et al. Coagulation factor Ⅺ is a contaminant in intravenous immunoglobulin preparations [J]. Am J Hematol, 2000, 65 (1):30-34
  • 10Jesmos GJ,Tsay GC,Thompson TE.Acute pathophysidogic effects of systemic complement activation in the cyomolgus monky [J]. J Leukocyte Biol Abstract, 19,90(Suppl):1-42

共引文献19

同被引文献51

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部